Thus, pretreatment melanoma samples from patients who displayed a clinical response to anti-PD-1 therapy showed higher CD8+ T cell frequencies compared to samples from patients with progressive disease during therapy [47], indicating that pre-existing tumor-infiltrating CD8+ T cells are predictors of a clinical response to PD-1 blockade. Here, CD8A is linked to melanoma.